Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05398627 · ClinicalTrials.gov registry record · NA
Neurofeedback for Borderline Personality Disorder
A NA study of Borderline Personality Disorder, sponsored by Kymberly Young.
- Active
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05398627: Active NA study of Borderline Personality Disorder, sponsored by Kymberly Young.
NCT05398627 is a NA study of Borderline Personality Disorder that is active but no longer recruiting, run by Kymberly Young. The registered enrollment target is 100 participants, roughly in line with the 101-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05398627, a NA study of Borderline Personality Disorder, is active but no longer recruiting, sponsored by Kymberly Young.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.
Primary Outcome
Assessment of severity of borderline symptoms. This scale contains 24 items rated on a four-point scale (0=false to 3=very true). Scores range from 0-72, and are converted to T scores, with higher scores indicating more borderline symptoms. Scores below 59 indicate healthy, scores at or above 70T indicate the respondent is likely to have borderline personality disorder.
Conditions Studied
Interventions
- DEVICE Amygdala Neurofeedback
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-09-02 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT05398627 still lists
NCT05398627 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 101-participant average among 16 other Borderline Personality Disorder trials with a reported enrollment target.
The record links to 1 condition, with Borderline Personality Disorder appearing as the primary indexed condition, and to 1 intervention - of which Amygdala Neurofeedback is the first listed.
NCT05398627 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05398627 about?
NCT05398627 is a clinical study titled "Neurofeedback for Borderline Personality Disorder". The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.
What is the current status of trial NCT05398627?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-09-02. Estimated completion is 2026-04-30.
What conditions does trial NCT05398627 study?
This clinical trial studies the following conditions: Borderline Personality Disorder.
What interventions are being tested in trial NCT05398627?
The interventions under investigation include: Amygdala Neurofeedback (DEVICE).
Who is sponsoring clinical trial NCT05398627?
This trial is sponsored by Kymberly Young, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05398627 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Borderline Personality Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05398627's enrollment target sits among peer trials
100 5th of 16 higher than 12 of 16 other Borderline Personality Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Borderline Personality Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
RECRUITING · NA
-
Cognitive Reappraisal Training for Borderline Personality (BPD)
RECRUITING · NA
-
Treatment of Borderline Personality Disorder With rTMS
RECRUITING · NA
-
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
RECRUITING · NA
-
PILOT Phase: BPD Study
ACTIVE NOT RECRUITING · NA
-
Personality Change Study for Borderline Personality Disorder
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI